A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors

Summary

This is a Phase 1/2a, first-in-human, open-label study of JAB-8263, this study has two parts: solid tumor dose escalation and expansion study and hematology tumor dose escalation and expansion study. These two parts will determine the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D) and assess the DLT of JAB-8263 in treatment with patients with advanced solid tumors and hematology tumors separately. 30 subjects each will be enrolled.

Timeline

Start

2021-05-07

Primary completion

2028-01

Completion

2028-07

Drugs

Indications